Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Solna – page 22

377 clinical trials in Solna, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Solna at a glance
377
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

377 trials in Solna

Open in trial search

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Mantle cell lymphoma

Not recruiting

Study Comparing Rituximab with Ibrutinib to Rituximab with Chemotherapy for Older Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Region Skane

Plasma cell myeloma

Not recruiting

Study on the Safety and Tolerability of OsteoDex for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Osteodex
  • Sponsor:Dextech Medical AB

Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency

Not recruiting

Study on INZ-701 for Improving Survival in Infants with ENPP1 Deficiency

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Ovarian cancer

Not recruiting

Study on the Safety and Tolerability of KAND567 and Carboplatin for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Kancera AB

Gastrointestinal stromal tumour

Not recruiting

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Crohn's disease

Not recruiting

Study on the Safety and Effectiveness of AZD7798 for Adults with Ileal Crohn's Disease and an Ileostomy

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Azd7798
  • Sponsor:AstraZeneca AB

Hidradenitis

Not recruiting

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Keratosis follicular

Not recruiting

Study on Dantrolene Sodium for Treating Darier Disease in Affected Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dantrolene Sodium
  • Sponsor:Karolinska University Hospital

Ovarian cancer

Not recruiting

Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

EGFR gene mutation+1

Not recruiting

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Vestre Viken HF

Other cities in Sweden

The busiest research cities in the country

All 65 cities in Sweden

Clinical research in Solna

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on advanced cancer treatments, including studies for prostate cancer, melanoma, breast cancer, and lung cancer. Research aims to evaluate new therapeutic approaches and combination treatments.

  • Metastatic Prostate Cancer Therapy
  • Stage III Melanoma Treatment
  • Advanced Breast Cancer Management
  • Early-Stage Lung Cancer Intervention

Studies evaluate innovative therapies and compare their effectiveness to standard treatments.

02 Metabolic and Endocrine Disorders

Research investigating treatments for metabolic conditions and hormonal disorders, including obesity, diabetes, and polycystic ovary syndrome.

  • Obesity Management Studies
  • PCOS Treatment Alternatives
  • Diabetes Response Mechanisms

Trials examine both conventional and alternative therapeutic approaches.

03 Respiratory and Immunological Studies

Investigations into respiratory conditions and immune system responses, focusing on asthma, nasal polyps, and pediatric respiratory disorders.

  • Asthma Treatment Innovation
  • Chronic Rhinosinusitis Management
  • Pediatric Wheezing Prevention

Research aims to develop more effective treatments and preventive strategies.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.